Journal · Industry & Trends
If 2026 was the year regenerative aesthetics went mainstream, 2027 is the year it becomes the expectation. Here are the ten shifts we believe will define the next twelve months, and what clinics can do now to be ready.
Patients increasingly want treatments that improve the skin itself rather than simply add volume. Expect regenerative options, from polynucleotides to biostimulators, to sit at the centre of treatment plans rather than as add-ons. In a 2026 US consumer survey reported by NewBeauty, preventing future ageing was the top goal for nearly three-quarters of respondents.
Under-eye, neck and overall skin-quality protocols built on PN and PDRN will become standard menu items. The differentiators in 2027 will be protocol, combination and results photography. See our polynucleotides guide.
With oral GLP-1 tablets now available in the UK, the number of people losing significant weight will keep rising. Clinics will build dedicated pathways: skin-quality support during loss, structural restoration afterwards and body laxity treatment. Read GLP-1s in 2026.
The overfilled look is firmly out. Expect lower volumes, more precise placement, more dissolving and re-treating, and greater use of softer, more dynamic HA fillers designed to move naturally.
Hybrid HA and skin boosters will continue to be the entry point for new patients, particularly younger “prejuvenation” patients who want glow and resilience without visible change.
Exosome products have exploded in popularity, but the evidence base and regulation are still catching up. Expect more scrutiny of claims, sourcing and route of use, and a premium on well-documented products. See exosomes explained.
England’s licensing scheme for non-surgical cosmetic procedures is still not in force, but the direction is set, and Scotland has moved ahead with its own legislation. Clinics that document training, consent, complications protocols and premises standards now will be ready whatever the final rules say. More in how 2026 changed aesthetics.
The line between aesthetic clinic and longevity clinic is blurring. Expect more clinics offering biological-age testing, nutrition and sleep coaching, and NAD+ and cellular energy support alongside injectables. Credibility will matter: patients are increasingly sophisticated and evidence-literate.
Combination protocols pairing RF, HIFU and microneedling with injectables will continue to outperform single-modality treatment for laxity and texture.
From facial analysis to treatment simulation and aftercare follow-up, AI tools will become part of the consultation. The clinics that win will use them to improve communication and safety, not to replace clinical judgement.
In 2027 the question patients ask will not be “what can you fill?” but “what can you restore?”
Get 2027-ready in one basket.
Regenerative aesthetics: treatments that aim to improve skin biology and quality, including polynucleotides, biostimulators and skin boosters.
No, but how they are used is changing: lower volumes, more natural results and combination with skin-quality treatments.
Sources: NewBeauty, “State of Aesthetics, Summer 2026”; Save Face, aesthetic trends 2026; UK Government response on the licensing of non-surgical cosmetic procedures (2025).
Keep reading
Immortality is not on the horizon. But for the first time, therapies designed to slow or reverse parts of ageing are being tested in people. Here is what is real, what is hype and what it means for aesthetics.
In 2026 a therapy built on David Sinclair's epigenetic reprogramming research was given to people for the first time, in an attempt to restore sight lost to glaucoma and optic nerve stroke. Here is what the early data shows.
Oral GLP-1 tablets, higher-dose injections and millions of new patients. How the GLP-1 revolution moved on in 2026, and why it is reshaping aesthetic practice.
